|
|
N (%) |
Clinical Disease
pattern
|
Early onset AD
|
41 (71.9)
|
|
Adult onset AD |
16 (28.1) |
|
Persistent pattern |
43 (75.4) |
|
Relapsing pattern |
14 (24.6) |
Phenotype |
Classical flexural AD |
39 (68.4) |
|
Prurigo nodularis-like AD |
7 (12.3) |
|
Head/neck AD |
4 (7.0) |
|
Nummular type AD |
3 (5.3) |
|
Erythrodermic AD |
2 (3.5) |
|
Chronic hand eczema |
2 (3.5) |
Current Treatment |
Dupilumab |
28 (49.1) |
|
Antihistamines |
10 (17.5) |
|
Topical treatment |
10 (17.5) |
|
Cyclosporine |
5 (8.7) |
|
Upadacitinib |
2 (3.5) |
|
Methotrexate |
2 (3.5) |
|
Atopic comorbidities (asthma, rhinitis, conjunctivitis) |
17
(29.8) |
|
Thyroiditis |
4 (7.0) |
|
Alopecia |
3 (5.3) |
Comorbidities |
Hypertension |
2 (3.5) |
|
Inflammatory bowel disease |
2 (3.5) |
|
Metabolic syndrome, migraine, previous stroke, previous thyroid
carcinoma, and coeliac disease |
1 (1.7) |
|
|
Mean ± SD |
Objective and Subjective severity of AD |
Eczema Area and Severity Index
(EASI) |
9.11 ± 8.10 |
|
Patient-Oriented Eczema Measure (POEM) |
12.33 ± 8.68 |